Kieran S O'Brien1, Sun Y Cotter1, Abdou Amza2, Boubacar Kadri2, Beido Nassirou2, Nicole E Stoller1, Zhaoxia Zhou1, Sheila K West3, Robin L Bailey4, Jeremy D Keenan1,5, Travis C Porco1,6, Thomas M Lietman1,5,6. 1. From the Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California. 2. Programme FSS/Université Abdou Moumouni de Niamey, Programme National de Santé Oculaire, Niamey, Niger. 3. Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Marlyland. 4. Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom. 5. Departments of Ophthalmology. 6. Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California.
Abstract
BACKGROUND: Mass distributions of azithromycin for trachoma have been associated with secondary benefits, including reductions in child mortality. METHODS: In the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger, 24 communities were randomized to annual treatment of everyone and 24 communities were randomized to biannual treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a single dose of directly observed oral azithromycin (20 mg/kg up to 1 g in adults). Vital status was assessed during annual census and monitoring visits. In this prespecified secondary analysis, we compared the mortality rate among children 6 months to less than 5 years of age by treatment arm using negative binomial regression. RESULTS: Among children 6 months to less than 5 years of age, 404 deaths occurred during the study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI: 30.9-40.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI: 24.8-33.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the annual arm was 0.81 (95% CI: 0.66-1.00, P = 0.07; primary outcome). The mortality rate ratio comparing children who died from infectious causes in the biannual arm to the annual arm was 0.73 (95% CI: 0.57-0.94; P = 0.02). No adverse events were reported. CONCLUSIONS: This secondary analysis of a cluster-randomized trial found a nonsignificant 19% decrease in mortality among children 6 months to less than 5 years of age who receivedbiannual azithromycin compared with children who received annual azithromycin. This study was conducted in a high mortality, trachoma-endemic area; thus, results may be specific to this environment only. In addition, the trial was neither designed nor powered to detect a mortality effect, and we cannot rule out the possibility that mortality differences resulted from bias.
RCT Entities:
BACKGROUND: Mass distributions of azithromycin for trachoma have been associated with secondary benefits, including reductions in child mortality. METHODS: In the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger, 24 communities were randomized to annual treatment of everyone and 24 communities were randomized to biannual treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a single dose of directly observed oral azithromycin (20 mg/kg up to 1 g in adults). Vital status was assessed during annual census and monitoring visits. In this prespecified secondary analysis, we compared the mortality rate among children 6 months to less than 5 years of age by treatment arm using negative binomial regression. RESULTS: Among children 6 months to less than 5 years of age, 404 deaths occurred during the study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI: 30.9-40.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI: 24.8-33.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the annual arm was 0.81 (95% CI: 0.66-1.00, P = 0.07; primary outcome). The mortality rate ratio comparing children who died from infectious causes in the biannual arm to the annual arm was 0.73 (95% CI: 0.57-0.94; P = 0.02). No adverse events were reported. CONCLUSIONS: This secondary analysis of a cluster-randomized trial found a nonsignificant 19% decrease in mortality among children 6 months to less than 5 years of age who received biannual azithromycin compared with children who received annual azithromycin. This study was conducted in a high mortality, trachoma-endemic area; thus, results may be specific to this environment only. In addition, the trial was neither designed nor powered to detect a mortality effect, and we cannot rule out the possibility that mortality differences resulted from bias.
Authors: Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West Journal: Ophthalmic Epidemiol Date: 2011-02 Impact factor: 1.648
Authors: Jessica C Seidman; Christian L Coles; Ellen K Silbergeld; Joshua Levens; Harran Mkocha; Lashaunda B Johnson; Beatriz Muñoz; Sheila K West Journal: Int J Epidemiol Date: 2014-03-21 Impact factor: 7.196
Authors: Sheila K West; Jeanne Moncada; Beatriz Munoz; Harran Mkocha; Philip Storey; Justin Hardick; Charlotte A Gaydos; Thomas C Quinn; Julius Schachter Journal: J Infect Dis Date: 2014-01-19 Impact factor: 5.226
Authors: Jenafir I House; Berhan Ayele; Travis C Porco; Zhaoxia Zhou; Kevin C Hong; Teshome Gebre; Kathryn J Ray; Jeremy D Keenan; Nicole E Stoller; John P Whitcher; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Zhaoxia Zhou; Robin L Bailey; David C Mabey; Travis C Porco; Jeremy D Keenan; Bruce D Gaynor; Sheila K West; Thomas M Lietman Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079
Authors: Kevin Cyrus Hong; Julius Schachter; Jeanne Moncada; Zhaoxia Zhou; Jenafir House; Thomas M Lietman Journal: Emerg Infect Dis Date: 2009-07 Impact factor: 6.883
Authors: Jessica C Seidman; Lashaunda B Johnson; Joshua Levens; Harran Mkocha; Beatriz Muñoz; Ellen K Silbergeld; Sheila K West; Christian L Coles Journal: Front Microbiol Date: 2016-09-07 Impact factor: 5.640
Authors: Kieran S O'Brien; Abdou Amza; Boubacar Kadri; Baido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Catherine E Oldenburg Journal: Am J Trop Med Hyg Date: 2018-07-12 Impact factor: 2.345
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26
Authors: Catherine E Oldenburg; Ahmed M Arzika; Ramatou Maliki; Mohamed Salissou Kane; Elodie Lebas; Kathryn J Ray; Catherine Cook; Sun Y Cotter; Zhaoxia Zhou; Sheila K West; Robin Bailey; Travis C Porco; Jeremy D Keenan; Thomas M Lietman Journal: PLoS Negl Trop Dis Date: 2018-11-12
Authors: Ali Sié; Boubacar Coulibaly; Clarisse Dah; Mamadou Bountogo; Mamadou Ouattara; Guillaume Compaoré; Jessica M Brogdon; William W Godwin; Elodie Lebas; Thuy Doan; Benjamin F Arnold; Travis C Porco; Thomas M Lietman; Catherine E Oldenburg Journal: BMC Pediatr Date: 2021-03-17 Impact factor: 2.125
Authors: Rebecca L Brander; Marcia R Weaver; Patricia B Pavlinac; Grace C John-Stewart; Stephen E Hawes; Judd L Walson Journal: Clin Infect Dis Date: 2020-01-06 Impact factor: 9.079
Authors: Catherine E Oldenburg; Ahmed M Arzika; Abdou Amza; Teshome Gebre; Khumbo Kalua; Zakayo Mrango; Sun Y Cotter; Sheila K West; Robin L Bailey; Paul M Emerson; Kieran S O'Brien; Travis C Porco; Jeremy D Keenan; Thomas M Lietman Journal: Am J Trop Med Hyg Date: 2019-03 Impact factor: 2.345
Authors: Catherine E Oldenburg; Abdou Amza; Gretchen Cooley; Boubacar Kadri; Beido Nassirou; Benjamin F Arnold; Philip J Rosenthal; Kieran S O'Brien; Sheila K West; Robin L Bailey; Travis C Porco; Jeremy D Keenan; Thomas M Lietman; Diana L Martin Journal: Malar J Date: 2019-12-03 Impact factor: 2.979